WO2007060002A3 - Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung - Google Patents
Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung Download PDFInfo
- Publication number
- WO2007060002A3 WO2007060002A3 PCT/EP2006/011308 EP2006011308W WO2007060002A3 WO 2007060002 A3 WO2007060002 A3 WO 2007060002A3 EP 2006011308 W EP2006011308 W EP 2006011308W WO 2007060002 A3 WO2007060002 A3 WO 2007060002A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- profile
- therapy
- genome
- prognosis
- recommendation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Die vorliegende Erfindung betrifft ein Verfahren zur individualisierten Prognose,- Therapieempfβhlung und/oder -Verfolgung und/oder Nachsorge einer Tumorerkrankung eines Patienten. Derartige Verfahren werden benötigt, um präzise Entscheidungskriterien für eine bestimmte Therapie bzw. die Wiederaufnahme einer Therapie zu erhalten. Erfindungsgemäß wird ein erstes Genomprofil oder Expressionsprofil einer ersten Probe enthaltend Tumorgewebe zum Zeitpunkt der Diagnose des Tumors erfasst wird, das den Genomstatus oder Expressionsstatus einer ersten Vielzahl menschlicher Gene enthält, für den jeweiligen Patienten für eine individuelle Auswahl an menschlichen Genen aus der Vielzahl von erfassten menschlichen Genen der Genomstatus oder Expressionsstatus gespeichert wird, zu einem späteren Zeitpunkt für die Gene der individuellen Auswahl ein weiteres Genomprofil oder Expressionsprofil einer zweiten Probe, enthaltend Lymphknotengewebe, Knochenmark und/oder eine Körperf lüssigkeit, erfasst und mit dem ersten Genomprofil oder Expressionsprofil verglichen, und aufgrund dieses Vergleichs eine Therapieempfehlung, eine Prognosebeurteilung oder eine Therapiebeurteilung durchgeführt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06829122A EP1957671A2 (de) | 2005-11-25 | 2006-11-24 | Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200510056365 DE102005056365A1 (de) | 2005-11-25 | 2005-11-25 | Verfahren zur individualisierten Prognose, Therapieempfehlung und/oder -verfolgung und/oder Nachsorge einer Tumorerkrankung |
DE102005056365.1 | 2005-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007060002A2 WO2007060002A2 (de) | 2007-05-31 |
WO2007060002A3 true WO2007060002A3 (de) | 2007-11-15 |
Family
ID=38037670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/011308 WO2007060002A2 (de) | 2005-11-25 | 2006-11-24 | Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1957671A2 (de) |
DE (1) | DE102005056365A1 (de) |
WO (1) | WO2007060002A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007051757A1 (de) | 2007-10-30 | 2009-05-07 | Ecker, Felix, Prof. Dr. | Verfahren zur automatischen Herstellung von patientenindividuell dosierten pharmazeutischen Zubereitungen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194701A1 (en) * | 2000-11-20 | 2003-10-16 | Golub Todd R. | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis |
US20020155480A1 (en) * | 2001-01-31 | 2002-10-24 | Golub Todd R. | Brain tumor diagnosis and outcome prediction |
AU2002354941A1 (en) * | 2001-07-17 | 2003-03-03 | Dana-Farber Cancer Institute, Inc. | Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia |
US20050074793A1 (en) * | 2003-04-04 | 2005-04-07 | Wilson Keith E. | Metastatic colorectal cancer signatures |
-
2005
- 2005-11-25 DE DE200510056365 patent/DE102005056365A1/de not_active Withdrawn
-
2006
- 2006-11-24 EP EP06829122A patent/EP1957671A2/de not_active Ceased
- 2006-11-24 WO PCT/EP2006/011308 patent/WO2007060002A2/de active Application Filing
Non-Patent Citations (8)
Title |
---|
BOSMA A J ET AL: "Detection of Ciculating Breast Tumor Cells by Differential Expression of Marker Genes", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 8, no. 6, June 2002 (2002-06-01), pages 1871 - 1877, XP002989678, ISSN: 1078-0432 * |
KODA MARIUSZ ET AL: "Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer.", ONCOLOGY REPORTS APR 2004, vol. 11, no. 4, April 2004 (2004-04-01), pages 753 - 759, XP002444940, ISSN: 1021-335X * |
MONTEL V ET AL: "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model", AMERICAN JOURNAL OF PATHOLOGY 2005 UNITED STATES, vol. 166, no. 5, 2005, pages 1565 - 1579, XP002444939, ISSN: 0002-9440 * |
PANTEL ET AL: "Detection and molecular characterisation of disseminated tumour cells: Implications for anti-cancer therapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 1, 25 September 2005 (2005-09-25), pages 53 - 64, XP005060826, ISSN: 0304-419X * |
SUELLEN TOTH-FEJEL ET AL: "DNA Fingerprints Provide a Patient-Specific Breast Cancer Marker", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 11, no. 6, 1 June 2004 (2004-06-01), pages 560 - 567, XP019369514, ISSN: 1534-4681 * |
TSUTSUI SHINICHI ET AL: "Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer", BREAST CANCER, JAPANESE BREAST CANCER SOCIETY, TOKYO, JP, vol. 9, no. 2, April 2002 (2002-04-01), pages 111 - 117, XP009087503, ISSN: 1340-6868 * |
WEIGELT B ET AL: "Gene expression profiles of primary breast tumors maintained in distant metastases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 23 DEC 2003 UNITED STATES, vol. 100, no. 26, 23 December 2003 (2003-12-23), pages 15901 - 15905, XP002444938, ISSN: 0027-8424 * |
ZIEGLSCHMID V ET AL: "DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD", CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, CRC PRESS, BACA RATON, FL, US, vol. 42, no. 2, 2005, pages 155 - 196, XP008066221, ISSN: 1040-8363 * |
Also Published As
Publication number | Publication date |
---|---|
EP1957671A2 (de) | 2008-08-20 |
WO2007060002A2 (de) | 2007-05-31 |
DE102005056365A1 (de) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006048881A3 (en) | A method and system for diagnosis of cardiac diseases utilizing neural networks | |
WO2008148115A8 (en) | Methods, systems, and kits for evaluating multiple sclerosis | |
WO2005029067A3 (en) | Method of diagnosing breast cancer | |
HK1063423A1 (en) | Methods to diagnose treat and prevent bone loss | |
EP1541193A4 (de) | MEDIZINISCHES BEHANDLUNGSSYSTEM UNTER VERWENDUNG EINES BIOLOGISCHEN REGULIERUNGSFUNKTIONSVERûNDERERS, SCHRITTMACHERSYSTEM AUF BASIS DES MEDIZINISCHEN BEHANDLUNGSSYSTEMS, BLUTDRUCKREGULIERSYSTEM UND SYSTEM ZUR BEHANDLUNG VON HERZKRANKHEITEN | |
WO2006089233A3 (en) | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia | |
WO2004044556A3 (en) | Diagnosis of sepsis or sirs using biomarker profiles | |
WO2006058306A3 (en) | Medical hyperspectral imaging for evaluation of tissue and tumor | |
WO2002053028A8 (en) | Electrical impedance method and apparatus for detecting and diagnosing diseases | |
MX2009003562A (es) | Ensayo elisa para la deteccion de vegf. | |
WO2006084272A3 (en) | Methods of predicting chemotherapy responsiveness in breast cancer patients | |
EP2503338A3 (de) | CD73 als Biomarker zur Überwachung der Entwicklung von Krankheiten und zum Testen der Wirksamkeit von Therapien | |
WO2005118875A3 (en) | Diagnosing or predicting the course of breast cancer | |
EP2365335A3 (de) | Diagnoseverfahren | |
Tolkachov et al. | Loss of the hematopoietic stem cell factor GATA2 in the osteogenic lineage impairs trabecularization and mechanical strength of bone | |
WO2007124820A3 (de) | Verfahren zur in-vitro überwachung postoperativer veränderungen nach lebertransplantation | |
WO2016146254A8 (en) | Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia | |
WO2004050907A3 (en) | Method for determing predisposition to manifestation of immune system related diseases | |
WO2007060002A3 (de) | Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung | |
EP1695092B8 (de) | Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie | |
CN105200137A (zh) | Cers2 基因及其表达产物作为骨质疏松症的诊治靶标 | |
Gallagher-Ross | Predictors of posttraumatic growth in breast cancer survivors: An analysis of hardiness, attachment, and cognitive appraisal | |
WO2009084898A3 (en) | System and method for analysing brain wave | |
MY147511A (en) | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker | |
WO2006136474A3 (de) | Verfahren zur ermittlung eines biomarkers zur kennzeichnung eines spezifischen biologischen zustands eines organismus aus mindestens einem datensatz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006829122 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006829122 Country of ref document: EP |